Related Experiment Videos
Parkinson's disease and osteoporosis
Frederiek van den Bos1, Arlene D Speelman, Monique Samson
1Internal Medicine, Haga Hospital, Leyweg 275, The Haque 2545 CH, The Netherlands. f.vandenbos@hagaziekenhuis.nl
Age and Ageing
|November 8, 2012
Summary
Parkinson's disease (PD) patients experience significant bone loss due to immobility, vitamin D deficiency, and hyperhomocysteinemia, increasing fracture risk. Early osteoporosis screening and intervention are crucial for managing bone health in PD.
Area of Science:
- Neurology
- Metabolic Bone Disease
- Gerontology
Background:
- Parkinson's disease (PD) patients face elevated risks of osteoporotic fractures.
- This risk is linked to falls and diminished bone mass.
- Understanding the mechanisms of bone loss in PD is critical for patient care.
Purpose of the Study:
- To review and summarize the pathophysiological mechanisms contributing to bone loss in Parkinson's disease.
- To consolidate current knowledge on bone metabolism alterations in PD.
Main Methods:
- A comprehensive literature search was conducted using Medline.
- Keywords included 'bone mineral density', 'osteoporosis', 'Parkinson's disease', and related terms.
- Articles published from January 1975 to January 2011 were analyzed.
Main Results:
- Parkinson's disease patients exhibit lower bone mineral density (BMD) compared to controls.
- Bone loss in PD is multifactorial, influenced by immobility, reduced muscle strength, low body weight, and vitamin D deficiency.
- Hyperhomocysteinemia, linked to levodopa use and vitamin deficiencies, is common and independently increases osteoporosis risk.
Conclusions:
- Bone loss in Parkinson's disease is a complex, multifactorial issue with significant clinical implications.
- The increased risk of fractures necessitates consideration for more frequent osteoporosis screening.
- Initiating therapeutic interventions, including bisphosphonates, vitamin D, and calcium, may improve BMD and reduce fracture incidence.
Related Concept Videos
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:29Bone Disorders
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:17Hormones and Bone Tissue
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...